Update on Diabetic Nephropathy: Core Curriculum 2018

Slides:



Advertisements
Similar presentations
Dinkar Kaw, M.D., Division of Nephrology
Advertisements

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Section 4: Managing progression of CKD
Robert C. Stanton, MD  American Journal of Kidney Diseases 
Chronic Kidney Disease in Diabetes
Mark A. Lusco, MD, Agnes B. Fogo, MD, Behzad Najafian, MD, Charles E
Mark A. Lusco, MD, Agnes B. Fogo, MD, Behzad Najafian, MD, Charles E
Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian, MD, Charles E
Management of hypertension in patients with chronic kidney disease
Richard J. Glassock, MD  American Journal of Kidney Diseases 
Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline  Krista L. Lentine, MD, PhD, Andrew S. Levey, MD,
Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.
Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian, MD, Charles E
American Journal of Kidney Diseases
American Journal of Kidney Diseases
Diabetic Nephropathy American Journal of Kidney Diseases
AJKD Atlas of Renal Pathology: Minimal Mesangial and Mesangial Proliferative Lupus Nephritis (ISN/RPS Class I and II)  Agnes B. Fogo, MD, Mark A. Lusco,
Behzad Najafian, MD, Mark A. Lusco, MD, Laura S. Finn, MD, Charles E
Cardiovascular Disease and CKD: Core Curriculum 2010
AJKD Atlas of Renal Pathology: Chronic Antibody-Mediated Rejection
Recurrent AA Amyloidosis in a Kidney Transplant
AJKD Atlas of Renal Pathology: Fibrillary Glomerulonephritis
AJKD Atlas of Renal Pathology: Acute Pyelonephritis
Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian, MD, Charles E
AJKD Atlas of Renal Pathology: Fabry Nephropathy
Sickle Cell Nephropathy
AJKD Atlas of Renal Pathology: Nail-Patella Syndrome–Associated Nephropathy  Behzad Najafian, MD, Kelly Smith, MD, PhD, Mark A. Lusco, MD, Charles E. Alpers,
AJKD Atlas of Renal Pathology: Collapsing Glomerulopathy
Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundation–Kidney Early Evaluation Program (KEEP) 2012.
AJKD Atlas of Renal Pathology: Cryoglobulinemic Glomerulonephritis
Your Kidneys May Outlive You
AJKD Atlas of Renal Pathology: Heavy Chain Deposition Disease
Erratum American Journal of Kidney Diseases
Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis  Xiaole Su, MD, Lu Zhang, MD, Jicheng Lv, MD, PhD, Jinwei Wang, PhD,
AJKD Atlas of Renal Pathology: Sickle Cell Nephropathy
Donor kidney biopsies: pathology matters, and so does the pathologist
Robert C. Stanton, MD  American Journal of Kidney Diseases 
Management of Heart Failure in Advancing CKD: Core Curriculum 2018
AJKD Atlas of Renal Pathology: Postinfectious Glomerulonephritis
AJKD Atlas of Renal Pathology: Chronic Pyelonephritis
AJKD Atlas of Renal Pathology: Cortical Necrosis
AJKD Atlas of Renal Pathology: Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits  Mark A. Lusco, MD, Agnes B. Fogo, MD, Behzad.
AJKD Atlas of Renal Pathology: Pierson Syndrome
AJKD Atlas of Renal Pathology: Alport Syndrome
American Journal of Kidney Diseases
Volume 65, Issue 6, Pages (June 2004)
AJKD Atlas of Renal Pathology: Light Chain Deposition Disease
Beef Tea, Vitality, Creatinine, and the Estimated GFR
AJKD Atlas of Renal Pathology: Membranous Nephropathy
AJKD Atlas of Renal Pathology: Thrombotic Microangiopathy
AJKD Atlas of Renal Pathology: Arterionephrosclerosis
Update on Diabetic Nephropathy: Core Curriculum 2018
AJKD Atlas of Renal Pathology: Toxic Acute Tubular Injury
Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian, MD, Charles E
AJKD Atlas of Renal Pathology: Idiopathic Nodular Sclerosis
AJKD Atlas of Renal Pathology: Systemic Sclerosis
Mark A. Lusco, MD, Agnes B. Fogo, MD, Behzad Najafian, MD, Charles E
Acute Kidney Injury and Proteinuria in a Patient With Diabetes and a Submandibular Mass  Prue Hill, MD, PhD, Prue Russell, MD, Christine Sammartino, MD,
AJKD Atlas of Renal Pathology: Anti–Glomerular Basement Membrane Antibody– Mediated Glomerulonephritis  Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian,
AJKD Atlas of Renal Pathology: Minimal Change Disease
AJKD Atlas of Renal Pathology: Diabetic Nephropathy
AJKD Atlas of Renal Pathology: Focal Segmental Glomerulosclerosis
AJKD Atlas of Renal Pathology: Acute Interstitial Nephritis
AJKD Atlas of Renal Pathology: IgA Nephropathy
IgA Nephropathy American Journal of Kidney Diseases
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
Pancreas Transplantation for the Prevention of Diabetic Nephropathy
Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian, MD, Charles E
Quiz Page Answers May 2006 American Journal of Kidney Diseases
IgA Nephropathy American Journal of Kidney Diseases
Presentation transcript:

Update on Diabetic Nephropathy: Core Curriculum 2018 Kausik Umanath, Julia B. Lewis  American Journal of Kidney Diseases  Volume 71, Issue 6, Pages 884-895 (June 2018) DOI: 10.1053/j.ajkd.2017.10.026 Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Pathophysiology of diabetic nephropathy. Abbreviations: AGE, advanced glycation end product; ECM, extracellular matrix. American Journal of Kidney Diseases 2018 71, 884-895DOI: (10.1053/j.ajkd.2017.10.026) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Kidney biopsy images of diabetic nephropathy. (A) Diffuse mesangial matrix expansion, increased mesangial hypercellularity, and prominent glomerular basement membranes in diabetic nephropathy. The basement membrane is uniformly thick without evident deposits (periodic acid–Schiff stain; original magnification, ×400). Reproduced from Fogo (Diabetic nephropathy. Am J Kidney Dis. 1999;34(5):E18-E19). (B) Diabetic nephropathy with (top) diffuse mesangial expansion and arteriolar hyalinosis (red arrow) and (bottom) nodular mesangial expansion (Kimmelstiel-Wilson nodules) and concomitant hyalinosis of afferent and efferent arterioles (red arrows; Jones silver stain). Reproduced from Najafian et al (Diabetic nephropathy. Am J Kidney Dis. 2015;66(5):e37-e38). (C) Arteriolar hyalinosis: both afferent and efferent arterioles, shown here at the vascular pole, are hyalinized in diabetic nephropathy. This insudation of plasma proteins is due to endothelial injury. In contrast to hypertensive lesions, for which only the afferent arteriole is affected, there is injury to both afferent and efferent arterioles in diabetic nephropathy. (Top left) There is also mesangial matrix expansion and prominent basement membranes and a focus of hyalin within the sclerotic area in the glomerulus (Jones' silver stain; original magnification, ×400). Reproduced from Fogo (Diabetic nephropathy. Am J Kidney Dis. 1999;34(5):E18-E19). All images reproduced from the original AJKD Atlas of Renal Pathology or the AJKD Atlas of Renal Pathology II with the permission of the copyright holder (National Kidney Foundation). American Journal of Kidney Diseases 2018 71, 884-895DOI: (10.1053/j.ajkd.2017.10.026) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 3 Risk for end-stage kidney disease increases as proteinuria increases and estimated glomerular filtration rate (eGFR) decreases. Incidence rate ratios of end-stage renal disease (ESRD) and cardiovascular (CV) death events by baseline albuminuria and GFR levels. The table below the figure shows the multivariate adjusted risk for ESRD for each albuminuria and eGFR category, accounting for the possibility of competing events between ESRD and CV death. Abbreviation: ACR, albumin-creatinine ratio. Reproduced from Packham et al (Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database. Am J Kidney Dis. 2012;59(1):75-83) with permission of the copyright holder (National Kidney Foundation). American Journal of Kidney Diseases 2018 71, 884-895DOI: (10.1053/j.ajkd.2017.10.026) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 4 Cumulative proportions of patients with the primary composite end point (A) and its components, a doubling of the base-line serum creatinine concentration (B). Irbesartan reduces the risk for the composite outcome of doubling of serum creatinine concentration, end-stage kidney disease, or death as compared to amlodipine or placebo. Reproduced from Lewis et al (Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. New Engl J Med. 2001;345:851-860) with permission of the copyright holder (Massachusetts Medical Society). American Journal of Kidney Diseases 2018 71, 884-895DOI: (10.1053/j.ajkd.2017.10.026) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions